; and (2) by striking paragraph (1) of section 1302(c) and inserting paragraphs (1) and (5) of section 1302(c) of the Patient Protection and Affordable Care Act . (c) Effective date The amendments made by subsections (a) and (b) shall take effect with respect to plans beginning after December 31, 2019. 206. Modification of trade negotiating objectives relating to intellectual property rights to ensure access to biological products Section 102(b)(5)(C) of the Bipartisan Congressional Trade Priorities and Accountability Act of 2015 ( 19 U.S.C. 4201(b)(5)(C) ) is amended by striking the end period and inserting the following: , including by ensuring that trade agreements do not require a party to provide biological product exclusivity of more than 7 years. . III Innovation 301. Innovation incentive fund for new and more effective treatments of bacterial infections Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.) is amended by adding at the end the following: 409K. Innovation incentive fund for new and more effective treatments of bacterial infections (a) Establishment of fund There is hereby established in the Treasury of the United States a revolving fund to be known as the Antibiotics Innovation Incentive Fund , which shall consist of funds transferred under subsection (b). (b) Amounts credited to the fund There are hereby authorized to be appropriated, and appropriated, to the Antibiotics Innovation Incentive Fund, for fiscal year 2020, out of any monies in the Treasury not otherwise appropriated, $2,000,000,000. Such funds shall remain available until expended. (c) Awards (1) In general During the 10-year period following the date of enactment of the Affordable Medications Act , the Director of the NIH, in accordance with the criteria under subsection (d) and the goals under subsection (e), shall award— (A) up to 3 market entry awards for qualifying products that provide added benefit for patients over existing therapies in the treatment of serious and life-threatening bacterial